Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Thymosin Beta-4: Regulatory Status
Current legal and regulatory status for Thymosin Beta-4 across jurisdictions. This page reflects the most recent verified information and is updated as regulatory actions occur.
Back to Thymosin Beta-4 overviewUnited States
⚗
Research Only
Compounding status: not listed for compounding — full-length biologics class. WADA: prohibited (S2 — peptide hormones, growth factors, related substances).
Last verified:
What This Means
Reclassification is not the same as FDA approval.
Even if Thymosin Beta-4 moves to Category 1, it remains an off-label therapeutic that requires physician supervision. Category 1 means it can be compounded under section 503A — it does not confer approved-drug status.